Both Quanterix Corporation (NASDAQ:QTRX) and EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) are Biotechnology companies, competing one another. We will compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix Corporation	33.34M	14.71	30.40M	-2.07	0.00
EyePoint Pharmaceuticals Inc.	3.06M	83.75	80.31M	-1.35	0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Quanterix Corporation and EyePoint Pharmaceuticals Inc.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

	Net Margins	Return on Equity	Return on Assets
Quanterix Corporation	-91.18%	-53.8%	-37.5%
EyePoint Pharmaceuticals Inc.	-2,624.51%	-414.6%	-142.9%

Liquidity

Quanterix Corporation’s Current Ratio and Quick Ratio are 4.1 and 3.8 respectively. The Current Ratio and Quick Ratio of its competitor EyePoint Pharmaceuticals Inc. are 2.6 and 2.6 respectively. Quanterix Corporation therefore has a better chance of paying off short and long-term obligations compared to EyePoint Pharmaceuticals Inc.

Insider and Institutional Ownership

Quanterix Corporation and EyePoint Pharmaceuticals Inc. has shares owned by institutional investors as follows: 68.6% and 56.4%. 11.9% are Quanterix Corporation’s share owned by insiders. Competitively, 0.6% are EyePoint Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Quanterix Corporation	6.51%	14.84%	28.61%	18.88%	14.25%	-7.03%
EyePoint Pharmaceuticals Inc.	-4.66%	-4.26%	1.35%	1.81%	77.17%	108.33%

For the past year Quanterix Corporation has -7.03% weaker performance while EyePoint Pharmaceuticals Inc. has 108.33% stronger performance.

Summary

Quanterix Corporation beats on 7 of the 10 factors EyePoint Pharmaceuticals Inc.

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and SR-X system that supports the detection capability of approximately six biomarkers per test. The company's products also comprise kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, assay development, and custom development services. Quanterix Corporation primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.